Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Figure 6

Expression of phospho and total JAK2 and STAT3 in control, paclitaxel and paclitaxel plus CYT387-treated HEY cells. (A) Expression and immunolocalisation of phospho (P)-JAK2 (Tyr-1007/1008) and phospho (P)-STAT3 (Tyr-705) in control, paclitaxel, CYT387 and combination of both treatments in HEY cell line was evaluated by immunofluorescence. Three independent experiments were performed in triplicate. The mean fluorescence intensity was quantified using Cell-R software. Significant variations between the groups are indicated by *P<0.05, *** P < 0.001. (B) The expression of total (T)-JAK2 and total (T)-STAT3 was evaluated and quantified as described in Figure 6 A. Magnification 200x; scale bar = 10 μM.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us